Following EMA, FDA restricts use of high-dose Xeljanz, warning of added risks for the blockbuster JAK
The FDA has come out with new restrictions on the use of Pfizer’s high-dose version of Xeljanz after researchers drew a direct line between the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
